Skip to main content

Health

SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. Projects proposed in response to this FOA must be applicable to one of the following areas: (1) cancer therapeutics; (2) cancer imaging technologies, interventional devices, and/or in vivo diagnostics; or (3) in vitro and ex vivo cancer diagnostics and prognostics. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.

LOI: 7/9/2019

Application: 8/9/2019

 

Revolutionizing Innovative, Visionary Environmental Health Research (RIVER) (R35 Basic Experimental Studies with Humans Required)

The NIEHS Revolutionizing Innovative, Visionary Environmental health Research (RIVER) program seeks to provide support for the majority of the independent research program for outstanding investigators in the Environmental Health Sciences, giving them intellectual and administrative freedom, as well as sustained support to pursue their research in novel directions in order to achieve greater impacts. The program seeks to identify individuals, regardless of career stage, with a potential for continued innovative and impactful research and combine their existing investigator-initiated research into a single award with a duration of up to 8 years and direct costs of $600,000 and potentially up to $750,000 based on current NIEHS funding to be consolidated into the award. This funding opportunity is intended for basic experimental studies with humans that aim to understand fundamental aspects of phenomena or observable facts without specific applications towards processes or products in mind. Types of studies that fit within this funding opportunity include those using human subjects to support a deeper understanding of the mechanisms underlying the effects of environmental exposures on human health, including molecular epidemiological studies.

LOI: 5/20/2019

Application: 6/20/2019

 

NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional)

The NIH Directors New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important problems relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's New Innovator Award Program complements ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators through R01 grants, which continue to be the major sources of NIH support for early stage investigators.

Application: 8/26/2019

 

Office of Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

BARDA encourages the advanced research, development, and acquisition of medical countermeasures such as vaccines, therapeutics, and diagnostics, as well as innovative approaches to meet the threat of CBRN agents, emerging infectious diseases, and pandemic influenza. Research and Development Areas of Interest: 1. CBRN Vaccines; 2. CBRN Antitoxins and Therapeutic Proteins; 3. Antibacterials; 4. Radiological/Nuclear Threat Medical Countermeasures; 5. Chemical Threat Medical Countermeasures; 6. Burn Medical Countermeasures; 7. Diagnostics; 8. Influenza and Emerging Infectious Diseases (IEID) Vaccines; 9. Influenza and Emerging Infectious Diseases (IEID) Therapeutics; 10. Respiratory Protective Devices; 11. Ventilators; 12. MCM Production Platform Systems; 13. Modeling as an Enabling Technology for Influenza, Emerging Infectious Disease, and CBRN Threats; and 14. Visual Analytics an Enabling Technology for Influenza, Emerging Infectious Disease, and CBRN Threats.

Quad Chart and White Paper: 4/30/2019

Proposal: 10/31/2019

 

National Biodefense Science Board – Call for Nominations

The Office of the Assistant Secretary for Preparedness and Response (ASPR), in the Department of Health and Human Services (HHS) seeks applications from qualified individuals for membership on the National Biodefense Science Board (NBSB) or (Board). Terms of five members expire December 31, 2019; therefore, the HHS Secretary (Secretary) will appoint five new voting members. Members of the NBSB are appointed by the HHS Secretary based on their expertise in scientific, technical and other matters of special interest to HHS regarding current and future chemical, biological, nuclear, and radiological agents, whether naturally occurring, accidental, or deliberate.  NBSB board members should be available to travel for in-person, public meetings (mostly in Washington, DC) for 5-8 days per year (potentially more) and available for periodic conference calls (1-3 hours per month).  Board members may need to conduct work (individual reading or writing, for example) outside of organized meetings to be prepared to address agenda items and help to develop board reports.

Nomination: 6/15/2019

 

Rehabilitation Research and Training Center (RRTC) on Employment of People with Intellectual and Developmental Disabilities

The purpose of the RRTCs, which are funded through the Disability and Rehabilitation Research Projects and Centers Program, is to achieve the goals of, and improve the effectiveness of, services authorized under the Rehabilitation Act through well-designed research, training, technical assistance, and dissemination activities in important topical areas as specified by NIDILRR. These activities are designed to benefit people with disabilities, family members, rehabilitation service providers, policymakers and other research stakeholders. The purpose of this particular RRTC is to conduct research, training, technical assistance, and related activities to contribute to improved employment outcomes of people with intellectual and developmental disabilities.

LOI: 5/3/2019

Application: 5/28/2019

 

Youth Engagement in Sports: Collaboration to Improve Adolescent Physical Activity and Nutrition (YES Initiative)

The YES Initiative seeks to support projects that address the HHS priority to expand youth participation in sports and encourage regular physical activity, especially for youth populations with lower rates of sports participation and communities with limited access to athletic facilities or recreational areas. YES Initiative applicants should address unhealthy physical activity and nutrition behaviors in racial/ethnic minority and socio-economically disadvantaged youth, including specifically girls, and provide opportunities to learn skills and gain experiences that contribute to more positive lifestyles and enhance their capacity to make healthier life choices. The YES Initiative intends to identify effective collaborations and/or existing community organizational partnerships that aim to improve physical activity and nutrition by increasing sports participation of racial/ethnic minority and/or socio-economically disadvantaged youth, including specifically girls. YES Initiative projects will develop and implement sports fitness programs based on successful evidenced based practices for youth engagement, using experimental design, and result in the identification of model sustainable strategies that increase participation in range of physical activities that support a healthy lifestyle and improve the overall health among youth who, at baseline, do not meet current physical activity guidelines. YES applicants must propose to implement programs that will serve at a minimum 130 males and/or females in 6th, 7th and/or 8th grades over the course of two years. Proposals must describe, using geographic indicators and data from representative probability-based samples surveys or other representative population data, the demographic characteristics of the populations to be served by the project, including race/ethnicity, gender, socio-economic status and geographic location.

Application: 5/31/2019

 

NIH Directors Early Independence Awards (DP5 Clinical Trial Optional)

The NIH Director's Early Independence Award supports exceptional investigators who wish to pursue independent research essentially after completion of their terminal doctoral/research degree or end of post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. Limited Submission Applications are submitted through this Sharepoint site.

Internal: 5/14/2019

LOI: 8/13/2019

Application: 9/13/2019

 

Institutional Translational Research Training Program (T32)

The purpose of the NINDS Institutional Translational Research Training Program is to equip trainees with the knowledge and skills needed to advance basic research toward clinical application. These programs will support, students and/or postdocs conducting basic, disease-relevant research in an environment that includes 1) basic neuroscientists and clinicians who are actively engaged in collaborative research projects, 2) neuroscience researchers with expertise in translational processes who are conducting research designed to move basic discoveries toward clinical application and 3) relationships with industry and government regulatory agencies. Programs will have a cohesive educational approach to translational training in areas relevant to the NINDS mission, and in which students and postdocs learn the processes involved in translational research in the context of their individual projects. Programs supported by this FOA must include activities that ensure a thorough understanding of experimental design, strong statistical and analytical skills, and skills for communicating science with a wide variety of audiences. These programs are intended to be 2 years in duration and support training of one or more of the following groups: advanced predoctoral students, postdoctoral fellows and fellowship-stage clinicians. Upon completion of the program, trainees will be prepared to address basic research problems with an understanding of the requirements for translating discoveries into viable therapies.

LOI: 4/29/2019

Proposal: 5/29/2019

 

Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites applications for development of translational research programs that are focused upon investigating cancer health disparities. The P20 grants will support feasibility and planning activities to build cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized Programs of Research Excellence (SPORE), addressing cancer health disparities as a cross-cutting research theme. All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. Furthermore, all research projects must be focused upon knowledge of human biology with a translational human endpoint proposed. All P20 grants must include a minimum of two well-developed translational research projects, as well as contribute significantly to the development of specialized shared resources core facilities, improved research model systems, and collaborative research activities with other institutions, P20 awardees, and/or current SPORE grantees.

LOI: 5/19/2019

Application: 6/19/2019

 

Advancing Manufacturing Processing and Control Strategies for Drug Substances and Drug Products (U01)- Clinical Trial Optional

The goal of this program is to support the advancement of regulatory science to facilitate the implementation and the assessment of continuous manufacturing and similar innovative monitoring and control techniques in the pharmaceutical sector. This will be accomplished by making awards to institutions of higher education and nonprofit organizations for the purpose of studying and recommending improvements to the process of continuous manufacturing of drugs and biological products (e.g., monoclonal antibodies and therapeutic enzymes). Examples of activities could include the development or modification of a novel manufacturing process (e.g., design, scale-up, and/or commercial scale), control method, and/or testing technology.

LOI: 4/1/2019

Application: 5/14/2019

 

 Department of Defense

Cancer Prevention and Research Institute of Texas

 

Multi-Site Study of the Health Implications of Exposure to PFAS-Contaminated Drinking Water

The Agency for Toxic Substances and Disease Registry (ATSDR) is soliciting research to commence a multi-site study on the human health effects of exposures to drinking water contaminated with per- and polyfluoroalkyl substances (PFAS). Proposed study sites must include communities using PFAS-contaminated private residential wells or public water systems. Exposure assessment will be based on measured PFAS serum levels as well as estimated PFAS serum levels derived from pharmacokinetic modeling of reconstructed PFAS drinking water concentrations over time. Specifically, grant awardees will be required to conduct historical reconstruction/water modeling in order to determine the PFAS concentration. Effect biomarkers such as lipids and tests of immune and thyroid function derived from pharmacokinetic modeling of reconstructed PFAS drinking water concentrations over time will be evaluated. ATSDR intends this research to be a two-part program consisting of (1) a mandatory core research protocol to allow ATSDR to aggregate the core data and to compare laboratory and statistical analyses across sites, and (2) each successful awardee will have the option to propose additional investigator-initiated research questions and hypotheses related to the overall goals of this NOFO.

Application: 5/30/2019

American Association for Cancer Research 

National Aeronautics and Space Administration

Appendix D: Topics in Human Health Countermeasures, Human Factors, and Behavioral Performance

Results of previous studies on the ISS have indicated that six months of spaceflight increase stiffness of the carotid and femoral arteries and insulin resistance in astronauts (Hughson et al., 2016; Arbeille et al., 2016). Other aspects of the cardiovascular system’s adaptation to weightlessness have been studied, including for example systolic and diastolic function, cardiac chamber size and wall thickness, risk of arrhythmia, and risk of coronary artery atherosclerosis. The health and clinical effects of these findings are currently being debated and tested in space, and it is not known, whether longer duration flights could augment them. In addition, the efficiency of the in-flight exercise countermeasures to protect the cardiovascular system against increased vascular stiffness as well as against cardiac atrophy for one year in space is not known. The purpose of this topic is therefore to understand if there are augmented cardiovascular health risk effects of extending missions to one year on ISS and the temporal profile of cardiovascular adaptation.

Step 1 proposal: 4/29/2019

Step 2 proposal: 7/9/2019

Patient-Centered Outcomes Research Institute (PCORI)

National Science Foundation